IJR News

AstraZeneca Announces $1.5 Billion Pipeline Savings Plan — Oct 27, 2026AstraZeneca announced a restructuring program expected to deliver about $1.5 billion in savings to support drug-development investments and its goal of $80 billion in annual revenue by 2030, after quarterly results beat expectations. The company is also considering cancer-vaccine development, though executives say rivals are better positioned in personalized vaccines for now and AstraZeneca sees challenges in scaling the technology.

0

Trial finds AstraZeneca drug doubles gastric cancer survivalHealth — Oct 25, 2026AstraZeneca says its experimental drug sonesitatug vedotin extended overall survival by about five months and nearly doubled survival for people with advanced stomach cancer after earlier treatments. The late-stage trial did not show a statistically significant improvement in disease-progression outcomes, and experts say more evidence is needed before broader use earlier in treatment.

+2

Nicole Hardy Five extra months of survival is real progress for advanced stomach cancer but the lack of clear progression benefit means doctors should stay cautious on early use.

AstraZeneca and Oracle begin AI project to speed trial recruitment — Oct 20, 2026AstraZeneca and Oracle signed a non-binding AI deal on Oct. 20, 2026; first program with M42 targets uncontrolled hypertension for trial recruitment in Abu Dhabi.

0

Dana Whitfield This partnership could finally speed up finding the right patients for new blood pressure treatments.

AstraZeneca signs $1.5 billion AI drug-discovery deal — Oct 15, 2026AstraZeneca will pay insitro $40M upfront and up to $1.46B in milestones for Virtual Human AI work on MASH and heart disease; Barr says early finds keep them ahead of journals.

0

Sam Okafor This kind of AI partnership could finally speed up real options for MASH patients who have few treatments now.

Amgen Reports Combo Cuts Lung Cancer Death Risk 58%Health — Oct 24, 2026A Phase 3 trial found that adding Amgen’s Imdelltra to AstraZeneca’s Imfinzi as maintenance therapy for extensive-stage small cell lung cancer reduced the risk of death by 58%, with median survival of 21.1 months versus 12.7 months on Imfinzi alone. The combination also delayed disease progression, though serious treatment-related side effects were more common than with Imfinzi alone.

+1

Priya Raman That's a solid gain in survival for extensive stage patients, worth weighing against the extra side effects.

Most Influential Women in World HistoryYourlist — RankingFrom ancient queens who ruled empires to modern activists who changed laws, these women left indelible marks on politics, science, and culture. Vote for who you think shaped history most profoundly.

AstraZeneca invests $2 billion in Summit cancer drug partnership — Sep 28, 2026AstraZeneca will invest $2 billion in Summit Therapeutics convertible preferred shares, with Summit stock up more than 17% after-hours ahead of a November 14 FDA decision on ivonescimab.

+1

Marcus Bell This deal could help bring the cancer drug to market faster if the November decision goes well.

AstraZeneca Pauses Coronavirus Vaccine Trial, Rollout Doubts Dent SharesReporting — Sep 9, 2020AstraZeneca has paused global trials of its experimental coronavirus vaccine after an unexplained illness in a participant, denting the British drugmaker’s shares on Wednesday as the move was seen as dimming prospects…

0

AstraZeneca Shot Is Good If Safety Issues Can Be Overcome, Fauci SaysReporting — Apr 13, 2021U.S. infectious disease official Anthony Fauci said AstraZeneca’s COVID-19 vaccine had good efficacy, but safety concerns needed to be straightened out and it might not be needed for Americans because of supplies of…

0

AstraZeneca US Trial Data a Confidence Booster for COVID-19 ShotReporting — Mar 22, 2021AstraZeneca’s COVID-19 vaccine performed better than expected in a major late-stage trial, potentially paving the way for its emergency authorization in the United States and bolstering confidence in the shot after…

0

AstraZeneca Says US Data Load for US COVID-19 Vaccine Approval Very BigReporting — Apr 30, 2021AstraZeneca is working as fast as possible to compile data on its COVID-19 vaccine to apply for U.S. approval but the dataset is very big, executives said on Friday as the drugmaker faces delays to its submission…

0

Investigation Finds ‘Clear’ Link Between AstraZeneca COVID-19 Vaccine and Blood Clots in BrainReporting — Apr 6, 2021A link between AstraZeneca’s COVID-19 vaccine and rare blood clots in the brain has been discovered, but officials have yet to identify a possible cause, according to a senior European Medicines Agency official. “In my…

0

Toy Story vs ShrekYourlist — VS BattleThe toy box vs the swamp: two animation revolutions, one inevitable playground argument.

AstraZeneca Resumes UK Trials of COVID-19 Vaccine Halted by Patient IllnessReporting — Sep 13, 2020AstraZeneca <AZN.L> has resumed British clinical trials of its COVID-19 vaccine, one of the most advanced in development, after getting the green light from safety watchdogs, the company said on Saturday. The late-stage…

0

US Secures 300 Million Doses of Potential Astrazeneca COVID-19 VaccineReporting — May 21, 2020The United States has secured almost a third of the first 1 billion doses planned for AstraZeneca’s experimental COVID-19 vaccine by pledging up to $1.2 billion, as world powers scramble for medicines to get their…

0

AstraZeneca India CFO Bhavana Agrawal to resignBusiness — Jul 21, 2026AstraZeneca Pharma India said CFO and Whole-Time Director Bhavana Agrawal will resign to take a regional role within the AstraZeneca Group, effective August 31, 2026, with a multi‑week handover and a search for a successor. Regulatory filings confirm the move as part of global realignment, while the company notes strong FY2025-26 growth, including about 33% higher revenue and solid PAT, underscoring ongoing operational resilience.

0

US To Share Up to 60 Million AstraZeneca Vaccine Doses Globally: White HouseReporting — Apr 26, 2021The United States will start to share up to 60 million doses of AstraZeneca Plc’s coronavirus vaccine with other countries as soon as the next few weeks, the White House said on Monday. White House Press Secretary Jen…

0

How charismatic are you, really?Quizie — QuizNot a score out of ten — the AI identifies your specific brand of charm and where it's most dangerous.

Exclusive: US Plans To Send 4 Million Doses of AstraZeneca Vaccine to Mexico, CanadaReporting — Mar 18, 2021The United States plans to send roughly 4 million doses of AstraZeneca’s COVID-19 vaccine that it is not using to Mexico and Canada in loan deals with the two countries, an administration official told Reuters on…

0

AstraZeneca Completes $2B Summit Cancer Drug InvestmentBusiness — Oct 2, 2026AstraZeneca has completed its $2 billion equity investment in Summit Therapeutics to accelerate development of ivonescimab, an investigational PD-1/VEGF cancer antibody. The companies are also advancing clinical collaborations that pair ivonescimab with antibody-drug conjugates across several cancers, including lung and breast cancer.

0

Coroner Rules Young Doctor Died from Blood Clot Due to COVID Vaccine – Wife Wants Death Certificate ChangedReporting — Apr 24, 2023A London Coroner’s Court has ruled that the blood clot that killed British psychologist Stephen Wright in January 2021 was linked to the AstraZeneca COVID-19 vaccine. The AstraZeneca vaccine is not approved for use in…

0

AstraZeneca Says COVID-19 Vaccine 76 Percent Effective in New Analysis, To Seek US ApprovalReporting — Mar 25, 2021AstraZeneca’s said its COVID-19 vaccine was 76% effective in a new analysis of its U.S. trial – only a tad lower than the level in an earlier report this week criticised for using outdated data. Interim data published…

0

Myriad Genetics, SOPHiA GENETICS and AstraZeneca advance prostate cancer biomarkerHealth — Oct 8, 2026Myriad Genetics, SOPHiA GENETICS and AstraZeneca are collaborating to advance Myriad’s prostate cancer genomic instability score, designed to identify tumors with features associated with homologous recombination deficiency. Myriad’s MyChoice CDx test will generate the score, while SOPHiA plans to develop a decentralized companion diagnostic; the technology is being studied for clinical trials and is not yet an approved prostate cancer test.

0

AstraZeneca Posts Q2 Beat, Reaffirms 2026 Outlook — Jul 24, 2026AstraZeneca beat second-quarter profit expectations and reaffirmed its 2026 outlook despite concerns about future growth after a trial setback, as investors await further details on its earnings trajectory. Analysts are mixed but broadly positive, with several buy ratings and a focus on the upcoming Q2 results and oncology-driven revenue, amid a broader market backdrop of cautious trading ahead of earnings.

0

AstraZeneca Breast Cancer Trial Misses Key Goal — Sep 11, 2026AstraZeneca’s breast cancer pill camizestrant (Etcamah) failed to improve progression-free survival in a late-stage trial when added to standard therapy, despite an earlier ESR1 mutation–targeted approval and after-hours stock weakness. The broader trial that reached more patients failed, while a separate study in ESR1-mutant patients showed a meaningful benefit, underscoring a split outcome for the drug’s potential.

+3

Marcus Bell It's frustrating the overall trial missed but good the ESR1 group still saw real benefit from the drug.

EU Approves Etcamah in First-Line ER+ Breast Cancer — Jul 23, 2026AstraZeneca’s Etcamah (camizestrant) won EU approval to be used with CDK4/6 inhibitors as a first-line treatment for ER-positive, HER2-negative advanced breast cancer in patients with ESR1 mutations, based on SERENA-6 trial results showing a 56% reduction in progression or death. The drug already has approvals in Japan, the UAE, and Saudi Arabia, with U.S. review ongoing and the EU decision highlighting its potential to expand AstraZeneca’s oncology footprint as it targets endocrine-resistant disease.

0

US NIH Director Says Will Not Compromise on Coronavirus Vaccine SafetyReporting — Sep 9, 2020The pause of AstraZeneca Plc’s <AZN.L> coronavirus vaccine trials due to an unexplained illness in a study participant shows that safety of vaccines will not be compromised, the head of the National Institutes of Health…

0